PDCD1LG2 and cancer: We also evaluated the association between KDM5C expression and several inhibitory (e.g., CD160, CD96, CSF1R, CTLA-4, TIM-3, IDO1, IL10, LAG3, PD-1, PD-L1, PD-L2, TFGB1, TGFBR1, TIGIT, VEGFA) and stimulatory (e.g., CD27, CD28, CD40, CD40LG, CD70, CD80, CD86, CXCL12, CXCR4, ICOS, ICOSLG, MICA, MICB, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF4, TNFRSF9, TNFSF9, TNFSF13) immune checkpoints expression in various cancers.